Hidetomo Murakami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5530903/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Japanese multicenter database of healthy controls for [1231]FP-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1405-1416.	6.4	80
2	Effect of istradefylline on mood disorders in Parkinson's disease. Journal of the Neurological Sciences, 2019, 396, 78-83.	0.6	35
3	New mode of burst spinal cord stimulation improved mental status as well as motor function in a patient with Parkinson's disease. Parkinsonism and Related Disorders, 2018, 57, 82-83.	2.2	23
4	The Montreal Cognitive Assessment and Neurobehavioral Cognitive Status Examination are useful for screening mild cognitive impairment in Japanese patients with Parkinson's disease. Neurology and Clinical Neuroscience, 2013, 1, 103-108.	0.4	14
5	Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naÃ⁻ve Parkinson's disease. BMC Neurology, 2019, 19, 113.	1.8	11
6	Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson's disease. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2719-2726.	2.2	10
7	Correlation between motor and cognitive functions in the progressive course of Parkinson's disease. Neurology and Clinical Neuroscience, 2013, 1, 172-176.	0.4	9
8	Increased detection of mild cognitive impairment with type 2 diabetes mellitus using the Japanese version of the Montreal Cognitive Assessment: A pilot study. Neurology and Clinical Neuroscience, 2015, 3, 89-93.	0.4	7
9	Usefulness Differs Between the Visual Assessment and Specific Binding Ratio of 123I-Ioflupane SPECT in Assessing Clinical Symptoms of Drug-NaÃ⁻ve Parkinson's Disease Patients. Frontiers in Aging Neuroscience, 2018, 10, 412.	3.4	7
10	Face pareidolia is associated with right striatal dysfunction in drug-naÃ⁻ve patients with Parkinson's disease. Neurological Sciences, 2021, 42, 5327-5334.	1.9	6
11	Accumulation of 123I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-NaÃ⁻ve Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 321.	3.4	4
12	The subjective perception of past, present, and future time in patients with Alzheimer's disease: a qualitative study. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3185-3192.	2.2	4
13	Differences in correlations of depression and anhedonia with cardiovascular sympathetic functions during a head-up tilt test in drug-naÃ⁻ve Parkinson's disease patients. Neurological Sciences, 2020, 41, 2825-2830.	1.9	4
14	Modified <scp>S</scp> ix <scp>E</scp> lements <scp>T</scp> est: <scp>E</scp> arlier diagnosis of the correlation between motor and executive dysfunction in <scp>P</scp> arkinson's disease without dementia. Neurology and Clinical Neuroscience, 2015, 3, 209-214.	0.4	3
15	Improvement in Language Function Correlates with Gait Improvement in Drug-naÃ⁻ve Parkinson's Disease Patients Taking Dopaminergic Medication. Journal of Parkinson's Disease, 2016, 6, 209-217.	2.8	3
16	Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 616357.	3.4	3
17	Cerebrospinal fluid 5-HIAA concentrations correlate with cardiac uptake of 123I-MIBG during myocardial scintigraphy in drug naÃ⁻ve Parkinson's disease. Journal of Neural Transmission, 2018, 125, 1511-1514.	2.8	2
18	Altered Fibrinogen and Prothrombin mRNA Expression in Streptozotocin-induced Diabetic Rats. The Showa University Journal of Medical Sciences, 2000, 12, 295-302.	0.1	2

19 [P3–289]: COGNITIVE DOMAIN CORRELATES WITH STRIATAL ACCUMULATION OF DOPAMINE TRANSPORTER 0.8 0 SCINTIGRAPHY IN DRUG NAÃVE PARKINSON'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1053.	#	Article	IF	CITATIONS
	19	[P3–289]: COGNITIVE DOMAIN CORRELATES WITH STRIATAL ACCUMULATION OF DOPAMINE TRANSPORTER SCINTIGRAPHY IN DRUG NAÃVE PARKINSON'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1053.	0.8	0

P3â€412: ¹²³lâ€MIBG MYOCARDIAL SCINTIGRAPHY CAN BE A MARKER OF LANGUAGE FUNCTION IN <i>DE NOVO</i> PARKINSON'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1263. 0